Article
The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Aug 2005
Zhang X-T, Li L-Y, Mu X-L, Cui Q-C, Chang X-Y, Song W, Wang S-L, Wang M-Z, Zhong W, Zhang L
Abstract excerpt
BACKGROUND: The aim of the study was to evaluate the efficacy of gefitinib and the epidermal growth factor receptor (EGFR) mutation to gefitinib response in a series of Chinese patients with pretreated advanced non-small-cell lung cancer (NSCLC). METHODS: A total of 98 patients who had failed at least one platinum-based regimen received gefitinib 250 mg once daily. The mutation analysis of the EGFR kinase domain...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.